Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to -$123.3 million.

  • Marimed's Retained Earnings fell 1865.56% to -$123.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$123.3 million, marking a year-over-year decrease of 1865.56%. This contributed to the annual value of -$113.4 million for FY2024, which is 1349.91% down from last year.
  • Marimed's Retained Earnings amounted to -$123.3 million in Q3 2025, which was down 1865.56% from -$118.8 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Retained Earnings peaked at -$83.9 million during Q4 2022, and registered a low of -$123.3 million during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$97.4 million (2021), whereas its average is -$98.9 million.
  • As far as peak fluctuations go, Marimed's Retained Earnings surged by 1641.89% in 2021, and later crashed by 2031.76% in 2024.
  • Marimed's Retained Earnings (Quarter) stood at -$97.4 million in 2021, then grew by 13.83% to -$83.9 million in 2022, then fell by 19.1% to -$100.0 million in 2023, then fell by 13.5% to -$113.4 million in 2024, then fell by 8.69% to -$123.3 million in 2025.
  • Its Retained Earnings stands at -$123.3 million for Q3 2025, versus -$118.8 million for Q2 2025 and -$117.6 million for Q1 2025.